SCHEMBL7052865

SCHEMBL7052865

CC(C)(C)OC(=O)N/N=C/c1ccc(-c2ccccn2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.61
RAB9A P51151 7/20 0.60
NPC1 O15118 5/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
RECQL P46063 1/20 0.60
MAPT P10636 6/20 0.58
HDAC3 O15379 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC2 Q92769 1/20 0.56
KDM4E B2RXH2 4/20 0.55
KMT2A Q03164 4/20 0.51
LMNA P02545 2/20 0.51
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.50
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052868 1.00 MIF (0.61) MIFRAB9ANPC1SMN1; SMN2RECQL
SCHEMBL13916291 1.00 MIF (0.61) MIFRAB9ANPC1SMN1; SMN2RECQL
SCHEMBL7716956 0.88 RAB9A (0.59) MIFRAB9ANPC1SMN1; SMN2RECQL
SCHEMBL7919338 0.88 LMNA (0.63) MIFRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL6444624 0.83 MAPT (0.72) MIFRAB9ANPC1SMN1; SMN2RECQL
SCHEMBL3550155 0.81 HDAC3 (0.65) RAB9ANPC1SMN1; SMN2MAPTHDAC3
SCHEMBL27076797 0.81 HDAC3 (0.65) RAB9ANPC1SMN1; SMN2MAPTHDAC3
SCHEMBL3550150 0.81 HDAC3 (0.65) RAB9ANPC1SMN1; SMN2MAPTHDAC3
SCHEMBL3266677 0.80 MAPT (0.76) MIFRAB9ANPC1SMN1; SMN2RECQL
SCHEMBL12979794 0.80 MAPT (0.76) MIFRAB9ANPC1SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0979820-B1 2-Phenylpyridine derivatives and production method thereof SUMIKA FINE CHEMICALS CO LTD (JP) 2003-05-07 EP claimed
US-6147218-A 2-phenylpyridine derivative and production method thereof SUMIKA FINE CHEMICALS CO., LTD. (JP) 2000-11-14 US claimed
EP-0979820-A1 2-Phenylpyridine derivatives and production method thereof SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2000-02-16 EP claimed
EP-2522367-B1 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2016-01-20 EP disclosed
US-9107956-B2 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2015-08-18 US disclosed
US-9095620-B2 Reagents NEKTAR THERAPEUTICS (US) 2015-08-04 US disclosed
EP-2262538-B1 OLIGOMER-AMINO ACID CONJUGATE NEKTAR THERAPEUTICS (US) 2014-12-10 EP disclosed
US-20140045770-A1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-13 US disclosed
WO-2012170792-A1 ATAZANAVIR METABOLITE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2012-12-13 WO disclosed
EP-2522367-A1 Oligomer-protease inhibitor conjugates Nektar Therapeutics (US) 2012-11-14 EP disclosed
US-20110269677-A1 Oligomer-Protease Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2011-11-03 US disclosed
US-20020022730-A1 Method for producing hydrazine derivative SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-21 US disclosed
US-6268503-B1 REACTING 2-(4-BROMOMETHYLPHENYL)PYRIDINE SALT OR 2-(4-DIBROMOMETHYLPHENYL)PYRIDINE WITH HEXAMETHYLENETETRAMINE AND WATER TO PROVIDE 4-(PYRIDIN-2-YL)BENZALDEHYDE SUMIKA FINE CHEMICALS CO., LTD. (JP) 2001-07-31 US disclosed
US-6268503-B1 REACTING 2-(4-BROMOMETHYLPHENYL)PYRIDINE SALT OR 2-(4-DIBROMOMETHYLPHENYL)PYRIDINE WITH HEXAMETHYLENETETRAMINE AND WATER TO PROVIDE 4-(PYRIDIN-2-YL)BENZALDEHYDE SUMIKA FINE CHEMICALS CO., LTD. (JP) 2001-07-31 US disclosed
US-6242608-B1 REACTING 4-(PYRIDIN-2-YL)BENZALDEHYDE WITH HYDRAZINE TO FORM 4-(PYRIDIN-2-YL)BENZALDEHYDE HYDRAZONE; CHEMICAL INTERMEDIATE TO AN ANTI-HIV DRUG SUMIKA FINE CHEMICALS CO., LTD. (JP) 2001-06-05 US disclosed
US-6242608-B1 REACTING 4-(PYRIDIN-2-YL)BENZALDEHYDE WITH HYDRAZINE TO FORM 4-(PYRIDIN-2-YL)BENZALDEHYDE HYDRAZONE; CHEMICAL INTERMEDIATE TO AN ANTI-HIV DRUG SUMIKA FINE CHEMICALS CO., LTD. (JP) 2001-06-05 US disclosed
US-6147218-A 2-phenylpyridine derivative and production method thereof SUMIKA FINE CHEMICALS CO., LTD. (JP) 2000-11-14 US disclosed
US-6147218-A 2-phenylpyridine derivative and production method thereof SUMIKA FINE CHEMICALS CO., LTD. (JP) 2000-11-14 US disclosed
EP-0979820-A1 2-Phenylpyridine derivatives and production method thereof SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2000-02-16 EP disclosed
EP-0979820-A1 2-Phenylpyridine derivatives and production method thereof SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2000-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022730-A1 Method for producing hydrazine derivative H1-2, H1-0, HRH2 MIF 4377/4885RAB9A 1851/4885NPC1 2765/4885
US-20140045770-A1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES DNPEP, ADAM17, SERPINB1 MIF 602/4885RAB9A 2708/4885NPC1 368/4885
US-20110269677-A1 Oligomer-Protease Inhibitor Conjugates ADAM17, DNPEP, SERPINB1 MIF 569/4885RAB9A 3122/4885NPC1 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.